423 related articles for article (PubMed ID: 30704421)
1. The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease.
Evans M; Palaka E; Furuland H; Bennett H; Linde C; Qin L; McEwan P; Bakhai A
BMC Nephrol; 2019 Jan; 20(1):31. PubMed ID: 30704421
[TBL] [Abstract][Full Text] [Related]
2. Development of a health economic model to evaluate the potential benefits of optimal serum potassium management in patients with heart failure.
Bakhai A; Palaka E; Linde C; Bennett H; Furuland H; Qin L; McEwan P; Evans M
J Med Econ; 2018 Dec; 21(12):1172-1182. PubMed ID: 30160541
[TBL] [Abstract][Full Text] [Related]
3. A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure.
Ward T; Lewis RD; Brown T; Baxter G; de Arellano AR
BMC Nephrol; 2023 Mar; 24(1):47. PubMed ID: 36890464
[TBL] [Abstract][Full Text] [Related]
4. The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K
Murphy D; Ster IC; Kaski JC; Anderson L; Banerjee D
BMC Nephrol; 2021 Jul; 22(1):254. PubMed ID: 34229607
[TBL] [Abstract][Full Text] [Related]
5. [Effect of hyperkalemia and RAASi nonadherence on patients affected by heart failure or chronic kidney disease].
Degli Esposti L; Perrone V; Giacomini E; Sangiorgi D; Alessandrini D; Santoro A
G Ital Nefrol; 2019 Sep; 36(5):. PubMed ID: 31580544
[TBL] [Abstract][Full Text] [Related]
6. Association of Changes in Creatinine and Potassium Levels After Initiation of Renin Angiotensin Aldosterone System Inhibitors With Emergency Department Visits, Hospitalizations, and Mortality in Individuals With Chronic Kidney Disease.
Garlo KG; Bates DW; Seger DL; Fiskio JM; Charytan DM
JAMA Netw Open; 2018 Nov; 1(7):e183874. PubMed ID: 30646338
[TBL] [Abstract][Full Text] [Related]
7. Cost Consequence Analysis of the Management of Hyperkalemia by Patiromer and Optimization of Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Chronic Kidney Disease Patients in Saudi Arabia.
Shaheen FAM; Meunier A; Altowaijri A; Faadhel TA; Al-Abdulkarim H; AlGabash A; Floros L
Saudi J Kidney Dis Transpl; 2022 Feb; 33(Supplement):S39-S52. PubMed ID: 37102523
[TBL] [Abstract][Full Text] [Related]
8. Clinical and Economic Impact of Hyperkalemia in Patients with Chronic Kidney Disease and Heart Failure.
Polson M; Lord TC; Kangethe A; Speicher L; Farnum C; Brenner M; Oestreicher N; Alvarez P
J Manag Care Spec Pharm; 2017 Apr; 23(4-a Suppl):S2-S9. PubMed ID: 28436256
[TBL] [Abstract][Full Text] [Related]
9. Maintaining Renin-Angiotensin-Aldosterone System Inhibitor Treatment with Patiromer in Hyperkalaemic Chronic Kidney Disease Patients: Comparison of a Propensity-Matched Real-World Population with AMETHYST-DN.
Chinnadurai R; Rengarajan S; Budden JJ; Quinn CM; Kalra PA
Am J Nephrol; 2023; 54(9-10):408-415. PubMed ID: 37725919
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness Analysis of Patiromer in Combination with Renin-Angiotensin-Aldosterone System Inhibitors for Chronic Kidney Disease in Sweden.
Widén J; Ivarsson M; Schalin L; Vrouchou P; Schwenkglenks M; Heimbürger O; Ademi Z; Sutherland CS
Pharmacoeconomics; 2020 Jul; 38(7):747-764. PubMed ID: 32239480
[TBL] [Abstract][Full Text] [Related]
11. Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study.
Jun M; Jardine MJ; Perkovic V; Pilard Q; Billot L; Rodgers A; Rogers K; Gallagher M
PLoS One; 2019; 14(3):e0213192. PubMed ID: 30845156
[TBL] [Abstract][Full Text] [Related]
12. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology.
Rosano GMC; Tamargo J; Kjeldsen KP; Lainscak M; Agewall S; Anker SD; Ceconi C; Coats AJS; Drexel H; Filippatos G; Kaski JC; Lund L; Niessner A; Ponikowski P; Savarese G; Schmidt TA; Seferovic P; Wassmann S; Walther T; Lewis BS
Eur Heart J Cardiovasc Pharmacother; 2018 Jul; 4(3):180-188. PubMed ID: 29726985
[TBL] [Abstract][Full Text] [Related]
13. Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors.
Kloner RA; Gross C; Yuan J; Conrad A; Pergola PE
J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):524-531. PubMed ID: 30103622
[TBL] [Abstract][Full Text] [Related]
14. Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors Secondary to Hyperkalemia Translates into Higher Cardiorenal Outcomes.
An J; Zhou H; Ni L; Harrision TN; Wei R; Agiro A; Brahmbhatt YG; Oluwatosin Y; Schilling CG; Sim JJ
Am J Nephrol; 2023; 54(7-8):258-267. PubMed ID: 37231821
[TBL] [Abstract][Full Text] [Related]
15. Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom.
Linde C; Bakhai A; Furuland H; Evans M; McEwan P; Ayoubkhani D; Qin L
J Am Heart Assoc; 2019 Nov; 8(22):e012655. PubMed ID: 31711387
[TBL] [Abstract][Full Text] [Related]
16. When should we start and stop ACEi/ARB in paediatric chronic kidney disease?
Chan EY; Ma AL; Tullus K
Pediatr Nephrol; 2021 Jul; 36(7):1751-1764. PubMed ID: 33057769
[TBL] [Abstract][Full Text] [Related]
17. Management of Hyperkalemia in Renin-Angiotensin-Aldosterone System Inhibitor: Strategies to Maintain Chronic Kidney Disease Patients with Type II Diabetes on Therapy.
Mahmud HA; Palmer BF
Cardiorenal Med; 2024; 14(1):191-201. PubMed ID: 38513618
[TBL] [Abstract][Full Text] [Related]
18. Discontinuation of RAAS Inhibition in Children with Advanced CKD.
van den Belt SM; Heerspink HJL; Kirchner M; Gracchi V; Thurn-Valsassina D; Bayazit AK; Niemirska A; Canpolat N; Kaplan Bulut I; Azukaitis K; Duzova A; Bacchetta J; Shroff R; Paripovic D; Özçakar ZB; Fidan K; Erdogan H; Gellermann J; Wühl E; de Zeeuw D; Melk A; Querfeld U; Schaefer F
Clin J Am Soc Nephrol; 2020 May; 15(5):625-632. PubMed ID: 32253275
[TBL] [Abstract][Full Text] [Related]
19. Prescription of renin-angiotensin-aldosterone system inhibitors (RAASi) and its determinants in patients with advanced CKD under nephrologist care.
Pecoits-Filho R; Fliser D; Tu C; Zee J; Bieber B; Wong MMY; Port F; Combe C; Lopes AA; Reichel H; Narita I; Stengel B; Robinson BM; Massy Z;
J Clin Hypertens (Greenwich); 2019 Jul; 21(7):991-1001. PubMed ID: 31169352
[TBL] [Abstract][Full Text] [Related]
20. Hyperkalemia in the Hypertensive Patient.
Lakkis JI; Weir MR
Curr Cardiol Rep; 2018 Mar; 20(2):12. PubMed ID: 29492706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
